Navigation Links
South Africa's Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
Date:11/9/2008

Partnership will help alleviate South African power crisis

JOHANNESBURG, South Africa and BOSTON Nov. 9 /PRNewswire/ -- Denham Capital, a leading energy-focused global private equity firm, announced today that it will invest equity of up to R1,5 billion (US $150 million, 95 million pounds Sterling) in BioTherm Energy, a South African developer, owner and operator of renewable and clean energy generation projects.

Commenting on Denham Capital's investment, Buyelwa Sonjica, South Africa Minister of Minerals and Energy said, "Having opened BioTherm's first plant just over a year ago, we are delighted with this substantial investment by Denham Capital, a major foreign investor, in a business that will generate more electricity in South Africa, contribute to the reduction of greenhouse gasses and create more jobs in the South African economy."

The Minister opened the 4.2 MW biogas to power plant, based at the PetroSA facility in Mossel Bay, east of Cape Town, in September 2007. At that time, it was the first private sector renewable power generation project in Southern Africa funded under the Clean Development Mechanism ("CDM") of the Kyoto Protocol, under which the project earns carbon credits because of its contribution to the reduction of greenhouse gasses. Under the European carbon-trading scheme these credits are in turn sold, primarily to European industries, which need to reduce the cost of their compliance liabilities.

The opportunity for small scale, on-site generation in South Africa has grown significantly and BioTherm Energy has secured, and is continuing to develop, a substantial pipeline in waste gas co-generation, biomass and combined heat and power projects, many of which qualify for carbon credits under the Kyoto Protocol. These projects can generate electricity much more rapidly than conventional large-scale power projects, thereby providing needed relief to the South African power system.

Dr. Louis van Pletsen,
'/>"/>

SOURCE Denham Capital; BioTherm Energy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
2. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
3. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
4. ORNL resilience plan to help Tennessee, Mississippi and South Carolina communities beat disaster
5. BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign
6. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
7. AG Mednet to Provide Image Network for Southwest Oncology Group
8. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
9. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
10. Medical University of South Carolina Opens State-of-the-Art Facility
11. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... DENVER, Colorado and JERUSALEM, September 16 Children,s,Hospital ... today,that Children,s Hospital is enrolling patients for the ExCell ... cord blood transplant sites,worldwide, five of which are children,s ... Hungary and Israel. The trial is researching the,safety and ...
... , ... Highly Automated QT(sm) and QT Beat-to-Beat(sm) to Improve Precision and Reduce Risk of False ... Rochester, ... core lab services and QT analysis, announced today that a top 15 pharmaceutical company ...
... , , , ST. LOUIS, ... be presenting at the UBS Global Life Sciences Conference on Monday, ... NY. Interested parties may listen via live audio broadcast over the ... the "Webcast" icon to access this file. , , ...
Cached Biology Technology:Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... University researchers is examining a new vaccine method that ... Wannemuehler and his team of researchers is hoping to ... use smaller doses and require only one trip to ... been prepared from killed bacteria. The vaccinated person,s immune ...
... available in French . A ... McGill Universitys Department of Microbiology and Immunology has discovered ... regulate the bodys autoimmune reactions may lose their effectiveness ... of type 1 diabetes. The study conducted on ...
... 2008 The Rwandan government, Great Ape Trust of ... Reserve is the future site of the Rwanda National ... ambitious forest restoration and ecological research efforts ever. The ... national conservation park comes less than three months after ...
Cached Biology News:Iowa State researchers look for smaller, cheaper, 1-dose vaccines 2Type 1 diabetes triggered by 'lazy' regulatory T-cells: McGill researchers 2Rwanda's Gishwati Forest selected as site for historic conservation project 2Rwanda's Gishwati Forest selected as site for historic conservation project 3
... designed for genome-wide microRNA expression profiling ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive microRNA Expression Profiling ... The Arabidopsis microRNA Microarray contains all ...
... MIDAS TRAQ systems integrate the unique ... Q TRAP and 3200 Q TRAP LC/MS/MS ... System plus automation software, to provide a ... protein biomarkers. , , Eliminate extensive ...
... and compact GC-8A is Shimadzu's basic gas ... simple to use, the GC-8A supports a ... on column injection port(s), and analog output. ... are available. The GC-8A is only 17.3 ...
... The PolarScreen Peroxisome Proliferator-Activated Receptor-gamma ... a sensitive and efficient method ... PPARGamma ligands using fluorescence polarization ... PPARGamma-Ligand binding domain (PPARGamma-LBD) with ...
Biology Products: